Compare OZ & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | ZURA |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | OZ | ZURA |
|---|---|---|
| Price | $50.28 | $6.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 8.9K | ★ 830.1K |
| Earning Date | 03-30-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,217,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 244.98 | N/A |
| 52 Week Low | $49.58 | $0.97 |
| 52 Week High | $82.89 | $6.88 |
| Indicator | OZ | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 30.92 | 58.88 |
| Support Level | $49.87 | $5.59 |
| Resistance Level | $51.56 | $6.88 |
| Average True Range (ATR) | 0.68 | 0.53 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 20.71 | 57.75 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.